Cytogenetic and molecular biological characterization of an adult medulloblastoma

Cancer Genetics and Cytogenetics

Volumn 178, Issue 2, 2007, Pages 104-113

  Holland, Heidrun ^a   Koschny, Ronald ^b,c   Krupp, Wolfgang ^d   Meixensberger, Jürgen ^d   Bauer, Manfred ^d   Schober, Ralf ^d   Kirsten, Holger ^a,e   Ganten, Tom M ^b   Ahnert, Peter ^a,e  

^a Faculty of Medicine   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CISPLATIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENETICS; CANCER RESISTANCE; CANCER THERAPY; CASE REPORT; CHROMOSOME 10Q; CHROMOSOME 11P; CHROMOSOME 14; CHROMOSOME 16Q; CHROMOSOME 18; CHROMOSOME 19; CHROMOSOME 1Q; CHROMOSOME 20; CHROMOSOME 20Q; CHROMOSOME 21; CHROMOSOME 22; CHROMOSOME 2P; CHROMOSOME 4Q; CHROMOSOME 8; CHROMOSOME 9Q; CHROMOSOME BANDING PATTERN; CHROMOSOME DELETION; CHROMOSOME DUPLICATION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 20; CHROMOSOME TRANSLOCATION 4; CHROMOSOME TRANSLOCATION 9; CHROMOSOME XQ; COMBINATION CHEMOTHERAPY; CYTOGENETICS; DISEASE SEVERITY; DRUG SENSITIZATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; HUMAN; KARYOTYPING; MEDULLOBLASTOMA; METAPHASE CHROMOSOME; MOLECULAR BIOLOGY; MONOTHERAPY; MUTATIONAL ANALYSIS; NEUROBLASTOMA CELL; NUMERICAL CHROMOSOME ABERRATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STAINING; STRUCTURAL CHROMOSOME ABERRATION; UNIPARENTAL DISOMY; WORLD HEALTH ORGANIZATION;

ADULT; CEREBELLAR NEOPLASMS; CHILD; CHROMOSOME ABERRATIONS; CHROMOSOME BANDING; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MATRIX METALLOPROTEINASE 2; MEDULLOBLASTOMA; PHOSPHOPYRUVATE HYDRATASE; POLYMORPHISM, SINGLE NUCLEOTIDE; SYNAPTOPHYSIN;

EID: 35348841496     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2007.06.005     Document Type: Article

References (54)

1. Cohen N., Betts D.R., Tavori U., Toren A., Ram T., Constantini S., Grotzer M.A., Amariglio N., Rechavi G., and Trakhtenbrot L. Karyotypic evolution pathways in medulloblastoma/primitive neuroectodermal tumor determined with a combination of spectral karyotyping, G-banding, and fluorescence in situ hybridization. Cancer Genet Cytogenet 149 (2004) 44-52
2. Giordana M.T., Schiffer P., Lanotte M., Girardi P., and Chio A. Epidemiology of adult medulloblastoma. Int J Cancer 80 (1999) 689-692
3. Holland H., Koschny R., Krupp W., Meixensberger J., Bauer M., Kirsten H., and Ahnert P. Comprehensive cytogenetic characterization of an esthesioneuroblastoma. Cancer Genet Cytogenet 173 (2007) 89-96
4. Bayani J., Pandita A., and Squire J.A. Molecular cytogenetic analysis in the study of brain tumors: findings and applications. Neurosurg Focus 19 (2005) E1
5. Mendrzyk F., Korshunov A., Toedt G., Schwarz F., Korn B., Joos S., Hochhaus A., Schoch C., Lichter P., and Radlwimmer B. Isochromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeats. Genes Chromosomes Cancer 45 (2006) 401-410
6. Cogen P.H., and McDonald J.D. Tumor suppressor genes and medulloblastoma. J Neurooncol 29 (1996) 103-112
7. Aldosari N., Wiltshire R.N., Dutra A., Schrock E., McLendon R.E., Friedman H.S., Bigner D.D., and Bigner S.H. Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft. Neurooncology 4 (2002) 75-85
8. Bayani J., Zielenska M., Marrano P., Kwan N.Y., Taylor M.D., Jay V., Rutka J.T., and Squire J.A. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg 93 (2000) 437-448
9. Hartmann W., Digon-Sontgerath B., Koch A., Waha A., Endl E., Dani I., Denkhaus D., Goodyer C.G., Sorensen N., Wiestler O.D., and Pietsch T. Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res 12 (2006) 3019-3027
10. Atlas of Genetics and Cytogenetics in Oncology and Haematology. http://AtlasGeneticsOncology.org. 2007.
11. Dorkeld F., Bernheim A., Dessen P., and Huret J.L. A database on cytogenetics in haematology and oncology. Nucleic Acids Res 27 (1999) 353-354
12. Sheikh B.Y., and Kanaan I.N. Medulloblastoma in adults. J Neurosurg Sci 38 (1994) 229-234
13. Rood B.R., Macdonald T.J., and Packer R.J. Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol 31 (2004) 666-675
14. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., and Smith C.A. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
15. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., and Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104 (1999) 155-162
16. Ganten T.M., Koschny R., Sykora J., Schulze-Bergkamen H., Buchler P., Haas T.L., Schader M.B., Untergasser A., Stremmel W., and Walczak H. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12 (2006) 2640-2646
17. Nakamura M., Rieger J., Weller M., Kim J., Kleihues P., and Ohgaki H. APO2L/TRAIL expression in human brain tumors. Acta Neuropathol (Berl) 99 (2000) 1-6
18. Fulda S., and Debatin K.M. 5-Aza-2′-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene 25 (2006) 5125-5133
19. Zuzak T.J., Steinhoff D.F., Sutton L.N., Phillips P.C., Eggert A., and Grotzer M.A. Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma. Eur J Cancer 38 (2002) 83-91
20. Sonnemann J., Kumar K.S., Heesch S., Muller C., Hartwig C., Maass M., Bader P., and Beck J.F. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 28 (2006) 755-766
21. Swansbury J. Introduction. Cancer cytogenetics: methods and protocols. Methods Mol Biol 220 (2003) 1-8
22. Seabright M. A rapid banding technique for human chromosomes. Lancet 2 (1971) 971-972
23. Huang J., Wei W., Zhang J., Liu G., Bignell G.R., Stratton M.R., Futreal P.A., Wooster R., Jones K.W., and Shapero M.H. Whole genome DNA copy number changes identified by high density oligonucleotide arrays. Hum Genomics 1 (2004) 287-299
24. Futreal P.A., Coin L., Marshall M., Down T., Hubbard T., Wooster R., Rahman N., and Stratton M.R. A census of human cancer genes. Nat Rev Cancer 4 (2004) 177-183
25. The Cancer Genome Project [Internet]. 2007. Available at: http://www.sanger.ac.uk/genetics/CGP/.
26. Muller A., Holzmann K., and Kestler H.A. Visualization of genomic aberrations using Affymetrix SNP arrays. Bioinformatics 23 (2007) 496-497
27. Ganten T.M., Haas T.L., Sykora J., Stahl H., Sprick M.R., Fas S.C., Krueger A., Weigand M.A., Grosse-Wilde A., Stremmel W., Krammer P.H., and Walczak H. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11 Suppl. 1 (2004) S86-S96
28. Li Y.C., Tzeng C.C., Song J.H., Tsia F.J., Hsieh L.J., Liao S.J., Tsai C.H., Van Meir E.G., Hao C., and Lin C.C. Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy. Clin Cancer Res 12 (2006) 2716-2729
29. Mitelman F., Johansson B., and Mertens F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat Genet 36 (2004) 331-334
30. Rabbitts T.H. Chromosomal translocations in human cancer. Nature 372 (1994) 143-149
31. Look A.T. Oncogenic transcription factors in the human acute leukemias. Science 278 (1997) 1059-1064
32. Rowley J.D. Chromosome translocations: dangerous liaisons revisited. Nat Rev Cancer 1 (2001) 245-250
33. Helman L.J., and Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 3 (2003) 685-694
34. Fitzgibbon J., Smith L.L., Raghavan M., Smith M.L., Debernardi S., Skoulakis S., Lillington D., Lister T.A., and Young B.D. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 65 (2005) 9152-9154
35. Karanjawala Z.E., Kaariainen H., Ghosh S., Tannenbaum J., Martin C., Ally D., Tuomilehto J., Valle T., and Collins F.S. Complete maternal isodisomy of chromosome 8 in an individual with an early-onset ileal carcinoid tumor. Am J Med Genet 93 (2000) 207-210
36. Pei J., Kruger W.D., and Testa J.R. High-resolution analysis of 9p loss in human cancer cells using single nucleotide polymorphism-based mapping arrays. Cancer Genet Cytogenet 170 (2006) 65-68
37. Teh M.T., Blaydon D., Chaplin T., Foot N.J., Skoulakis S., Raghavan M., Harwood C.A., Proby C.M., Philpott M.P., Young B.D., and Kelsell D.P. Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res 65 (2005) 8597-8603
38. Walker B.A., Leone P.E., Jenner M.W., Li C., Gonzalez D., Johnson D.C., Ross F.M., Davies F.E., and Morgan G.J. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 108 (2006) 1733-1743
39. Raghavan M., Lillington D.M., Skoulakis S., Debernardi S., Chaplin T., Foot N.J., Lister T.A., and Young B.D. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 65 (2005) 375-378
40. Nielaender I., Martin-Subero J.I., Wagner F., Martinez-Climent J.A., and Siebert R. Partial uniparental disomy: a recurrent genetic mechanism alternative to chromosomal deletion in malignant lymphoma. Leukemia 20 (2006) 904-905
41. Pietsch T., Waha A., Koch A., Kraus J., Albrecht S., Tonn J., Sorensen N., Berthold F., Henk B., Schmandt N., Wolf H.K., von Deimling A., Wainwright B., Chenevix-Trench G., Wiestler O.D., and Wicking C. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 57 (1997) 2085-2088
42. Vorechovsky I., Tingby O., Hartman M., Stromberg B., Nister M., Collins V.P., and Toftgard R. Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours. Oncogene 15 (1997) 361-366
43. Wolter M., Reifenberger J., Sommer C., Ruzicka T., and Reifenberger G. Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 57 (1997) 2581-2585
44. Xie J., Johnson R.L., Zhang X., Bare J.W., Waldman F.M., Cogen P.H., Menon A.G., Warren R.S., Chen L.C., Scott M.P., and Epstein Jr. E.H. Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res 57 (1997) 2369-2372
45. Raffel C. Molecular biology of the primitive neuroectodermal tumor: a review. Neurosurg Focus 7 (1999) e2.
46. Ehrbrecht A., Muller U., Wolter M., Hoischen A., Koch A., Radlwimmer B., Actor B., Mincheva A., Pietsch T., Lichter P., Reifenberger G., and Weber R.G. Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J Pathol 208 (2006) 554-563
47. Mendrzyk F., Radlwimmer B., Joos S., Kokocinski F., Benner A., Stange D.E., Neben K., Fiegler H., Carter N.P., Reifenberger G., Korshunov A., and Lichter P. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 23 (2005) 8853-8862
48. Biegel J.A., Rorke L.B., Packer R.J., Sutton L.N., Schut L., Bonner K., and Emanuel B.S. Isochromosome 17q in primitive neuroectodermal tumors of the central nervous system. Genes Chromosomes Cancer 1 (1989) 139-147
49. Gilhuis H.J., Anderl K.L., Boerman R.H., Jeuken J.M., James C.D., Raffel C., Scheithauer B.W., and Jenkins R.B. Comparative genomic hybridization of medulloblastomas and clinical relevance: eleven new cases and a review of the literature. Clin Neurol Neurosurg 102 (2000) 203-209
50. Collins V.P. Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 75 Suppl. 2 (2004) ii2-ii11
51. Eberhart C.G., Chaudhry A., Daniel R.W., Khaki L., Shah K.V., and Gravitt P.E. Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus. BMC Cancer 5 (2005) 19
52. Lamont J.M., McManamy C.S., Pearson A.D., Clifford S.C., and Ellison D.W. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10 (2004) 5482-5493
53. Duiker E.W., Mom C.H., de Jong S., Willemse P.H., Gietema J.A., van der Zee A.G., and de Vries E.G. The clinical trail of TRAIL. Eur J Cancer 42 (2006) 2233-2240
54. Koschny R., Ganten T.M., Sykora J., Haas T.L., Sprick M.R., Kolb A., Stremmel W., and Walczak H. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 45 (2007) 649-658